1.11
+0.3106(+38.85%)
Currency In USD
| Previous Close | 0.8 |
| Open | 0.88 |
| Day High | 1.42 |
| Day Low | 0.88 |
| 52-Week High | 171 |
| 52-Week Low | 0.53 |
| Volume | 71.35M |
| Average Volume | 686,618 |
| Market Cap | 5.97M |
| PE | -0.03 |
| EPS | -40.29 |
| Moving Average 50 Days | 1.15 |
| Moving Average 200 Days | 8.73 |
| Change | 0.31 |
If you invested $1000 in CERo Therapeutics Holdings, Inc. (CERO) since IPO date, it would be worth $1.12 as of April 24, 2025 at a share price of $1.11. Whereas If you bought $1000 worth of CERo Therapeutics Holdings, Inc. (CERO) shares 3 years ago, it would be worth $1.11 as of April 24, 2025 at a share price of $1.11.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
GlobeNewswire Inc.
10 hours ago
SOUTH SAN FRANSCISCO, Calif, April 24, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics
CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing
GlobeNewswire Inc.
Apr 22, 2025 12:15 PM GMT
SOUTH SAN FRANCISCO, Calif, April 22, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phago
CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company’s Lead Compound CER-1236
GlobeNewswire Inc.
Apr 10, 2025 12:15 PM GMT
Results in 17 Issued and Allowed Patent Applications Internationally with Nine Total Patent Families SOUTH SAN FRANSCISCO, Calif, April 10, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innov